Less than 1% of Australians with insomnia get the recommended treatment

What the data shows

Flinders University sleep researchers, working in partnership with the Sleep Health Foundation, published findings this month that fewer than 1% of Australians with clinical insomnia symptoms have ever received cognitive behavioural therapy for insomnia — the treatment most consistently supported by the evidence for long-term management of insomnia disorder. One in three young adults is not getting enough sleep. The recommended first-line treatment for those whose sleep difficulties meet diagnostic criteria is reaching fewer than one in a hundred of them.

If you have been struggling with sleep for months and your GP gave you a script rather than a referral, you are not a statistical anomaly. You are the norm. That norm is what researchers are now naming as an implementation failure — and beginning to address.

What CBTi actually is

Cognitive behavioural therapy for insomnia is not a vague instruction to improve “sleep hygiene.” It is a structured, protocol-driven programme — typically four to six sessions — designed to address the specific thought patterns and behavioural cycles that maintain insomnia once it has set in.

The key components are sleep restriction (deliberately limiting time in bed to consolidate sleep drive — counterintuitive, but effective), stimulus control (rebuilding the association between bed and sleep rather than wakefulness), and cognitive restructuring (working through the catastrophising thought loops that become a self-fulfilling physiological cycle: “if I don’t sleep, tomorrow is ruined”). Together, these approaches consistently outperform sleep medication in trials measuring durability of effect — the benefit is maintained after treatment ends, which is not reliably the case with pharmacological sleep aids.

Sleep medication works. For short-term insomnia — insomnia tied to an acute stressor, jet lag, grief, a medical procedure — the prescription pad is clinically reasonable and often appropriate. The issue the Flinders data is naming is not that sleeping pills exist. It is that many people end up on them long-term when CBTi, had they received it, might have resolved the underlying cycle without ongoing medication.

The both-and

Two things are simultaneously true about the CBTi access problem in Australia.

The first: CBTi is the established standard of care in Australian and international sleep medicine guidelines. The Sleep Health Foundation endorses it. RACGP guidance includes it. The evidence base is not contested. The clinical consensus for chronic insomnia is unusually clear for a behavioural intervention — it consistently outperforms sleeping tablets on long-term outcomes.

The second: access to accredited CBTi practitioners in Australia is genuinely limited. Trained CBTi providers are fewer in number than the demand requires. Face-to-face delivery means multiple appointments that fit a patient’s schedule, geography, and out-of-pocket budget. For many people — particularly those outside major metro centres — the practical path to an accredited practitioner is long. The 1% figure is not a reflection of people rejecting effective treatment. It is a reflection of access, awareness, and structural under-investment in non-pharmacological options in general practice.

Digital CBTi has emerged as the scalable response to this access gap. Self-paced digital programmes with strong randomised trial evidence for efficacy — comparable to in-person delivery in several trials — offer a low-barrier entry point. The Flinders team’s “Bedtime Window” programme (free, five sessions, structured for delivery through general practice) and the new “Sleep Spotlight” assessment tool being trialled in 2026 are part of this push. The 2026 COMISA trial from the same Flinders group, published in the Journal of Sleep Research, tested digital CBTi in people with co-morbid insomnia and obstructive sleep apnoea — a population often excluded from earlier CBTi trials — and found clinically meaningful results for both conditions simultaneously.

2 cents

If you have been managing sleep difficulty for more than three months and have not had a specific CBTi conversation with your GP, the access gap described above is your gap — not a statistical abstraction.

The practical ask is specific: when you next see your GP, ask for CBTi by name. Not “therapy for sleep,” not “something other than tablets” — cognitive behavioural therapy for insomnia, CBTi. If your GP is not familiar with local referral pathways, the Sleep Health Foundation credentialled practitioner directory is a direct resource. If cost and access are real barriers, ask specifically about digital CBTi programmes — several are free within Australian general practice settings.

The pattern insomnia creates is real. The physiology behind why it persists is well-characterised. The treatment for it is not indefinite medication. The system defaulting to the script pad is structural, not personal. And the structure is starting to shift.

This is general information, not personal medical advice. Insomnia has a range of causes and patterns. The specific clinical picture — whether you have sleep apnoea, a mood disorder, a medical condition contributing to sleep disruption — changes the conversation, and that conversation happens with your GP, not here.

Verdict

Verdict: yes — worth knowing about.

The CBTi access gap is one of the clearest implementation failures in Australian sleep medicine. The treatment is effective, the primary-tier evidence is solid, and fewer than 1% of people with insomnia are receiving it. The Flinders and Sleep Health Foundation digital tools are a practical, low-barrier starting point for people who want a non-medication approach to chronic insomnia. Asking your GP specifically about CBTi — by name — is the first step.

---

Sources cited

1. Flinders University — 1 in 3 young adults not getting enough sleep (May 2026)
2. Sleep Health Foundation — Cognitive Behavioural Therapy for Insomnia
3. Sweetman et al 2026 — Digital CBTi for COMISA — Journal of Sleep Research
4. Promoting sustained access to CBTi in Australia — PubMed